Aclaris Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aclaris Therapeutics generated cash of -$78,325,000, which is less than the previous year. Cash used in financing activities reached the amount of $26,706,000 last year. Net change in cash is therefore -$5,399,000.
Cash Flow
| 2014 | -7.63M | -1.77M | 10.58M |
|---|---|---|---|
| 2015 | -20.36M | -76.95M | 96.41M |
| 2016 | -34.60M | -61.90M | 116.82M |
| 2017 | -54.66M | -55.69M | 100.38M |
| 2018 | -100.81M | 9.36M | 128.26M |
| 2019 | -96.44M | 105.67M | -30.31M |
| 2020 | -38.63M | 6.38M | 18.37M |
| 2021 | -52.13M | -167.63M | 225.05M |
| 2022 | -67.56M | 12.62M | 72.86M |
| 2023 | -78.32M | 46.22M | 26.70M |
ACRS Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 45.27M | 27.34M | 22.06M | 35.93M | 57.01M | 20.20M | 30.17M | 9.85M | 10.75M | 9.58M |
Operating activities | ||||||||||
Net income | -88.48M | -86.90M | -90.86M | -51.01M | -161.35M | -132.73M | -68.52M | -48.07M | -20.56M | -8.51M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 863K | 797K | 923K | 1.32M | 6.40M | 1.87M | 402K | 120K | 90K | 12K |
Stock-based compensation expense | 20.54M | 15.03M | 14.06M | 11.20M | 16.17M | 0 | 14.43M | 6.10M | 891K | 27K |
| Deferred income tax benefit | 20.54M | 15.03M | 14.06M | 11.20M | 16.17M | 0 | 14.43M | 6.10M | 891K | 27K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 186K | 139K | 149K | 4.89M | -809K | -4.38M | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 605K | 102K | 0 | 0 | 0 | 0 |
Accounts payable | -1.47M | 368K | 3.65M | -5.21M | -3.16M | 6.96M | 4.56M | 1.81M | -359K | 819K |
Cash generated by operating activities | -78.32M | -67.56M | -52.13M | -38.63M | -96.44M | -100.81M | -54.66M | -34.60M | -20.36M | -7.63M |
Investing activities | ||||||||||
Purchases Of Investments | -135.67M | -164.75M | -235.15M | -47.71M | -137.38M | -161.59M | -197.33M | -148.76M | -82.51M | -5.03M |
Investments In Property Plant And Equipment | -1.30M | -605K | -308K | -453K | -1.61M | -1.35M | -1.23M | -232K | -507K | -417K |
Acquisitions Net | 0 | -13.23M | 167.32M | -6.84M | 34.18M | -67.12M | -9.64M | 0 | 0 | 0 |
Cash generated by investing activities | 46.22M | 12.62M | -167.63M | 6.38M | 105.67M | 9.36M | -55.69M | -61.90M | -76.95M | -1.77M |
Financing activities | ||||||||||
Common Stock Issued | 26.71M | 72.74M | 239.65M | 7.73M | 207K | 100.20M | 100.22M | 116.70M | 56.55M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -3.12M | 7.73M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -11.48M | -137K | -30.52M | -648K | -78K | 0 | 0 | 0 |
Cash used in financing activities | 26.70M | 72.86M | 225.05M | 18.37M | -30.31M | 128.26M | 100.38M | 116.82M | 96.41M | 10.58M |
Net Change In Cash | -5.39M | 17.92M | 5.28M | -13.87M | -21.08M | 36.81M | -9.96M | 20.32M | -906K | 1.16M |
Cash at end of period | 39.87M | 45.27M | 27.34M | 22.06M | 35.93M | 57.01M | 20.20M | 30.17M | 9.85M | 10.75M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |